CORT

Bullish

FDA cancer approval lifts Corcept (NASDAQ: CORT) 2026 outlook and spend

Corcept Therapeutics reported mixed Q1 2026 results with increased revenue but a net loss due to higher operating expenses for the Lifyorli launch and...

Stock Titan 3 days ago 0

Bearish

Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Corcept Therapeutics Incorporated (CORT). Investors wh...

PR Newswire 2 weeks ago 0